FDA pharmacologic class
Hepatitis C Virus NS3/4A Protease Inhibitor
0 medicines are in FDA's class of hepatitis c virus ns3/4a protease inhibitors: ; 3 combination products also contain one. 0 of the 3 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is mavyret 100-40 mg tablet at $152.98 per tablet (NADAC).
Which medicines are hepatitis c virus ns3/4a protease inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Glecaprevir and pibrentasvir | Mavyret | none listed | $152.98 per tablet 100-40 mg tablet | Yes | No current entry | 0 |
| Elbasvir and grazoprevir | Zepatier | none listed | n/a | Yes | A presentation being discontinued | 0 |
| Sofosbuvir and velpatasvir and voxilaprevir | Vosevi | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price